RadioTB trial: Optimal management of radiographically apparent, bacteriologically negative TB identified through active case finding
In plain English
AI plain-English summaryMillions of people each year now receive chest X-rays screened by computer software to find undiagnosed tuberculosis, but roughly 5–7% of those without prior TB show suspicious lung abnormalities while testing negative for the bacteria—and about 10% of them will develop infectious TB within a year. This group sits in a clinical blind spot. No one knows the best way to manage them: whether to treat with standard TB drugs, and if so, for how long. Current practice varies wildly, and the opportunity to prevent transmission and permanent lung damage is routinely missed. The last randomised trial in this population was conducted over 30 years ago. The RadioTB trial will run across South Africa, Zimbabwe, and Pakistan, embedded in existing screening programmes. It uses a pragmatic duration-response design to test the shortest standard regimen that stops progression. Alongside the trial, researchers will evaluate novel diagnostics, model transmission effects, and assess cost-effectiveness of different strategies. If successful, the trial could provide the first robust evidence in decades to guide global policy—turning a neglected, high-risk group into a target for early, efficient intervention that reduces TB spread and preserves lung health.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Discretionary AwardPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know